THC Biomed Intl Ltd C.THC

RE:The Most Undervalued Marijuana Company In The Sector!

[zenith9]

Go pump TRST somewhere else buddy. NOT HERE

TheJudger wrote: There’s a few companies that still have multibagger potential over the next few months leading up to recreational legalization.  The last couple of months have been awesome for huge gains and continue to be so.  Less than 12 days ago I more than doubled my $$ jumping into LEAF at $16.50 and then ABCN at $1.70.  With only 25 public marijuana companies in this space, it’s a hell of a lot easier doing due diligence on them, then say the hundreds of companies in the mining sector.  I’ve researched every company and in doing so have made some good calls for quick gains.  ABCN is my favourite sleeper play that should of caught on fire, but the botched Germany deal along with last quarter’s lacklustre financials kind of smouldered the flames so it’s going to take a while longer.

In the meantime I plan to double my $$ again by jumping into the most undervalued play right now.  This company speaks for itself with the lowest cost/gram in the industry and the highest percentage increase in marijuana patients to over 35,000 from 4000 last year.   While most are looking at late 2018 to early 2019 for first production from their new facility build outs, they’ll be producing 40,000kg/yr by July 2018.  This play is so undervalued compared to it’s peers that it could easily double in a few days, just as LEAF did.

2017 Third Quarter Highlights

• Record Revenues of $6.1M in Q3 2017, a 680% increase from the comparable prior year period
• Positive Net Income and Adjusted EBITDA
• Active patients increased to more than 31,000 compared to 4,700 in the comparable prior year period and 20,000 in the immediately preceding quarter ended June 30, 2017
• Cannabis extracts increased to over 61% of sales in the quarter
• Cannabis extraction capacity increased to 1.2 million bottles of oil per annum
• Average net selling price per gram of $8.78, an increase of 63% from the comparable prior year period
• Reduced cash cost per gram to $1.21¹ compared to $1.49 in the prior quarter

Developments subsequent to the Quarter

• Current sales exceeding $2.3 million per month
• Increased active patients to over 35,000
• Received a Health Canada Cultivation Licence under the ACMPR for our completed 250,000 square foot Phase 1 redevelopment of our 430,000 square foot Niagara Greenhouse Facility. Phase 1 was completed both on budget and on time
• Completed our first harvest from our Niagara Facility and full utilization from Phase 1 is expected in December 2017
• Increased our inventory storage capacity by approximately $93 million with the addition of three Level Nine Vaults at the Niagara Greenhouse Facility
• The planned Phase 2 expansion at the Niagara Facility is anticipated to be completed and in cultivation towards the middle of 2018. Phase 1 and 2 should conservatively provide the Company with an additional 40,000 kilograms of annual growing capacity
• Reached an agreement with a syndicate of underwriters pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 3,500,000 common shares of the Company, at a price of $5.00 per Common Share for aggregate gross proceeds to the Company of $17.5 million. The Company has also granted the Underwriters an Over-Allotment Option to purchase up to 500,000 additional Common Shares of the Company on the same terms as the Offering. The Underwriters have advised the Company that they will be exercising the Over-Allotment Option in full so that the aggregate gross proceeds of the Offering will be $20 million
• Arranged for a $15 million non-revolving demand loan on the Niagara Greenhouse Facility.  The terms presented to the Company remain subject to the lender’s credit committee approval
• The non-revolving demand loan  financing together with the bought deal Offering will fully fund the Company through the Phase 2 expansion at the Niagara Greenhouse Facility as well as provide funds for general and working capital purposes
• Received Health Canada approval to export medical marijuana internationally to Countries where medical marijuana is legalized and the Company began shipping to Australia. Australia is the first of many markets that the Company is expecting to supply. Other countries that we anticipate shipping to shortly are Germany, Denmark and Brazil
• Announced plans for the joint development of vapor products with Gilla Inc.
• Strengthened our Management Team with the addition of a VP of Marketing

“CannTrust is an experienced and advanced Licensed Producer of Pharmaceutical grade cannabis in Canada and our recently completed Phase 1 of our 430,000 square feet Niagara Facility is perfectly timed in order for us to supply the international orders we have recently received. The pending legislation to legalize the adult consumer recreational use of cannabis provides a further major opportunity for the Company. With the completion of all phases of our Niagara expansion we plan to have in excess of 1,000,000 square feet of production capacity. This will give us the ability to acquire a substantial share of the increased demand arising from these new markets” said Brad Rogers, President of CannTrust Inc.

“CannTrust has an amazing team, all of whom have helped build a business steeped in a culture of compliance and the highest standards” said Eric Paul CEO. “During the period we continued to experience dynamic growth in all areas of the Company as we continue to execute our business plan aimed at being a market leader and innovator in the development of products and services to better serve our patients and physicians.”

“Our pharmaceutically standardized, pesticide-free products and our physician education programs continue to position us as one of the premier providers resulting in exceptional new patient growth. Our plan was always to be a Pharmaceutical Company producing quality medical cannabis in a variety of unique dosage forms that will provide the best treatment options for patients. Our shipments to Australia are just the beginning of what we believe will be a World market opportunity for us along with our exclusive global pharma manufacturing partner, Apotex Inc.”

Add TRST to your watchlist and then watch it double before your eyes!